What is Monobind?
Headquartered in Costa Mesa, California, Monobind operates as a high-volume producer of diagnostic tools, having manufactured over 200 million immunoassays to date. The company serves a diverse clientele, including clinical laboratories, biomedical researchers, and global distributors across more than 30 countries. As a privately held corporation, Monobind distinguishes itself through a long-standing commitment to R&D authority and manufacturing excellence. Its market position is defined by its ability to provide cost-effective, reliable diagnostic solutions that meet rigorous international standards, effectively bridging the gap between complex laboratory requirements and scalable commercial production.
How much funding has Monobind raised?
Monobind has raised a total of $898K across 2 funding rounds:
Debt
$350K
Debt
$548K
Debt (2020): $350K with participation from PPP
Debt (2021): $548K led by PPP
Key Investors in Monobind
PPP
Public-Private Partnership
What's next for Monobind?
With the recent influx of capital, Monobind is well-positioned to accelerate its strategic initiatives, likely focusing on the expansion of its diagnostic portfolio and the enhancement of its global supply chain infrastructure. Given the company's established history and its role as a critical supplier in the healthcare ecosystem, this financing will likely support the scaling of its R&D capabilities to address emerging diagnostic challenges. Future growth trajectories will likely involve deepening market penetration in key international territories and optimizing production efficiencies to maintain its competitive edge in the high-stakes in-vitro diagnostics industry. The firm remains a pivotal player for stakeholders monitoring the intersection of diagnostic innovation and large-scale manufacturing.
See full Monobind company page
